Fig. 7From: Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine developmentAssociation of immune subtypes with CA19–9 and CA125. a-b Serum CA19–9 and CA125 level, respectively, in the GEO cohort. c-d Serum CA19–9 and CA125 level, respectively, in the TCGA cohortBack to article page